Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

362.01
Delayed Data
As of 3:59pm ET
 -6.94 / -1.88%
Today’s Change
325.35
Today|||52-Week Range
563.79
-33.32%
Year-to-Date
Cramer: With Trump, Everything's a Negotiation
7:03pm / TheStreet.com - Paid Partner Content
5 Top Performing Biotechnology Stocks of November
Dec 01 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions F...
10:02am / Zacks.com - Paid Partner Content
What Regeneron's CEO Thinks About Drug Pricing Under Trump
Dec 01 / TheStreet.com - Paid Partner Content
Play the Trump Factor with these 4 Large-Cap Stocks
Dec 06 / Zacks.com - Paid Partner Content
Buy 7 Stocks with Impressive Interest Coverage Ratio
Dec 01 / Zacks.com - Paid Partner Content
Here's Why Regeneron Pharmaceuticals, Inc. Jumped 9.4% in November
Dec 05 / MotleyFool.com - Paid Partner Content
NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted...
Nov 30 / Zacks.com - Paid Partner Content
Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age
Dec 02 / TheStreet.com - Paid Partner Content
Celgene vs. Regeneron: Which Stock is a Better Pick?
Nov 29 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close368.95
Today’s open365.28
Day’s range348.82 - 366.57
Volume1,681,153
Average volume (3 months)822,362
Market cap$38.9B
Dividend yield--
Data as of 3:59pm ET, 12/07/2016

Growth & Valuation

Earnings growth (last year)+79.80%
Earnings growth (this year)-3.14%
Earnings growth (next 5 years)+16.00%
Revenue growth (last year)+45.55%
P/E ratio52.8
Price/Sales15.24
Price/Book10.56

Competitors

 Today’s
change
Today’s
% change
ALXNAlexion Pharmaceutic...+1.45+1.17%
SHPGShire-7.97-4.61%
ZTSZoetis Inc+1.04+2.07%
BAXBaxter International...+0.13+0.30%
Data as of 4:02pm ET, 12/07/2016

Financials

Next reporting dateFebruary 14, 2017
EPS forecast (this quarter)$3.13
Annual revenue (last year)$4.1B
Annual profit (last year)$636.1M
Net profit margin15.50%

Profile

Sector
Health Technology
Industry
Biotechnology
President, CEO &
Class I Director
Leonard S. Schleifer
Chief Financial Officer &
Senior VP-Finance
Robert E. Landry
Corporate headquarters
Tarrytown, New York

Forecasts


Search for Jobs